Osteopontin in Metastatic Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

119

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

November 30, 2019

Conditions
Survival, Prosthesis
Interventions
DIAGNOSTIC_TEST

Osteopontin

Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.

Trial Locations (1)

35516

Mansoura University Oncology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04274504 - Osteopontin in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter